ReviewTherapeutic advances in cardiovascular disease2016
Understanding mechanisms of hypertension in systemic lupus erythematosus.
Review in Therapeutic advances in cardiovascular disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Risk and protective factors of disease flare during pregnancy in systemic lupus erythematosus: a systematic review and meta-analysis.Clinical rheumatology · 2025Pooled it
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- SLE Presenting With Unilateral Loculated Pleural Effusion in a Young Hypertensive Female: A Rare Case Report and Literature Review.Clinical case reports · 2026Article
- Acetylcholinesterase inhibitor therapy mitigates hypertension in lupus mice.Clinical science (London, England : 1979) · 2026Article
- Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus.International urology and nephrology · 2026Article
- Article
- Article
- Leptin antagonism attenuates hypertension and renal injury in an experimental model of autoimmune disease.Clinical science (London, England : 1979) · 2023Article
- Article
- Role of Inflammatory Processes in the Brain-Body Relationship Underlying Hypertension.Current hypertension reports · 2023Review
- Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus.Biomedicines · 2023Review
- Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?Kidney international reports · 2023Review
- Renal TLR-7/TNF-α pathway as a potential female-specific mechanism in the pathogenesis of autoimmune-induced hypertension.American journal of physiology. Heart and circulatory physiology · 2022Article
- Lymphatics in Cardiovascular Physiology.Cold Spring Harbor perspectives in medicine · 2022Review
- Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models.International journal of molecular sciences · 2022Article
- Trimethylamine N-Oxide Promotes Autoimmunity and a Loss of Vascular Function in Toll-like Receptor 7-Driven Lupus Mice.Antioxidants (Basel, Switzerland) · 2021Article
- Gut Microbiota Has a Crucial Role in the Development of Hypertension and Vascular Dysfunction in Toll-like Receptor 7-Driven Lupus Autoimmunity.Antioxidants (Basel, Switzerland) · 2021Article
- Class switching and high-affinity immunoglobulin G production by B cells is dispensable for the development of hypertension in mice.Cardiovascular research · 2021Article
- Contribution of Th17 cells to tissue injury in hypertension.Current opinion in nephrology and hypertension · 2021Review
- Proliferative Glomerulonephritis: Risk Factor for Hypertension in Lupus.International journal of hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predominately affects women of reproductive age. Hypertension is an important cardiovascular risk factor that is prevalent in this patient population. Despite the high incidence of hypertension in women with SLE, the pathophysiological mechanisms underlying the development of hypertension remain poorly understood. This review will focus on disease-related factors, including inflammation, autoantibodies, and sex hormones that may contribute to hypertension in patients with SLE. In addition, we will highlight studies performed by our laboratory using the female NZBWF1 (F1 hybrid of New Zealand Black and New Zealand White strains) mouse model, a spontaneous model of SLE that mimics human disease and develops hypertension and renal injury. Specifically, using female NZBWF1 mice, we have demonstrated that multiple factors contribute to the pathogenesis of hypertension, including the inflammatory cytokine, tumor necrosis factor (TNF)-α, oxidative stress, as well as B-cell hyperactivity and autoantibody production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.